EPYGENIX THERAPEUTICS

Epygenix Therapeutics is a clinical stage biopharmaceutical company developing the precision medicine for rare and refractory genetic epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome

Technology
Our technology rapidly identifies antiepileptic drugs and monitors toxicology – Epygenix Therapeutics used an innovative zebrafish-based platform applying phenotype-based in vivo screening.

Therapeutic Focus
Epygenix Therapeutics focuses on development of new treatments for rare and catastrophic forms of genetic epilepsy, including Dravet Syndrome, Lennox-Gastaut Syndrome, Infantile Spasm, Cute Syndrome, and Ohtahara Syndrome.

Clinical Trial
Epygenix Therapeutics is doing clinical trials to test drug candidates who have been identified with proprietary Zebrafish-based screening system.

What is Epygenix?

Epygenix Therapeutics is a clinical stage biopharmaceutical company developing drugs that treat Dravet syndrome (DS) and other genetic epilepsies. DS is a rare and catastrophic form of intractable epilepsy that begins in infancy. Current therapeutic options are not sufficient, and the constant care required can severely impact the quality of life for the entire family. Dravet syndrome, like most genetic forms of epilepsy, represents an orphan indication with an unmet medical need.

Seeking partnerships